A207940 Stock Overview
Samsung Biologics Co.,Ltd. engages in the contract manufacturing organization (CMO) business for biopharmaceuticals products.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for A207940 from our risk checks.
Samsung Biologics Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩711,000.00 |
| 52 Week High | ₩871,000.00 |
| 52 Week Low | ₩668,000.00 |
| Beta | 0.49 |
| 1 Month Change | -0.14% |
| 3 Month Change | -3.00% |
| 1 Year Change | -18.28% |
| 3 Year Change | -13.82% |
| 5 Year Change | 112.56% |
| Change since IPO | 393.75% |
Recent News & Updates
Recent updates
With EPS Growth And More, Samsung BiologicsLtd (KRX:207940) Is Interesting
Mar 01
These 4 Measures Indicate That Samsung BiologicsLtd (KRX:207940) Is Using Debt Reasonably Well
Jan 18
What Kind Of Shareholders Own Samsung Biologics Co.,Ltd. (KRX:207940)?
Dec 28How Much Is Samsung Biologics Co.,Ltd. (KRX:207940) CEO Getting Paid?
Dec 08Did You Miss Samsung BiologicsLtd's (KRX:207940) Impressive 112% Share Price Gain?
Nov 18Shareholder Returns
| A207940 | KR Life Sciences | KR Market | |
|---|---|---|---|
| 7D | 0.3% | 0.4% | 0.5% |
| 1Y | -18.3% | -17.0% | 4.4% |
Return vs Industry: A207940 underperformed the KR Life Sciences industry which returned -17% over the past year.
Return vs Market: A207940 underperformed the KR Market which returned 4.4% over the past year.
Price Volatility
| A207940 volatility | |
|---|---|
| A207940 Average Weekly Movement | 3.4% |
| Life Sciences Industry Average Movement | 7.4% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in KR Market | 12.1% |
| 10% least volatile stocks in KR Market | 2.9% |
Stable Share Price: A207940 is less volatile than 75% of KR stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: A207940's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 4,284 | John Chongbo Rim | https://samsungbiologics.com |
Samsung Biologics Co.,Ltd. engages in the contract manufacturing organization (CMO) business for biopharmaceuticals products. The company operates in two segments, CMO and Contract Development Organization (CDO).
Samsung Biologics Co.,Ltd. Fundamentals Summary
| A207940 fundamental statistics | |
|---|---|
| Market Cap | ₩50.60t |
| Earnings (TTM) | ₩936.92b |
| Revenue (TTM) | ₩3.59t |
54.0x
P/E Ratio14.1x
P/S RatioIs A207940 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A207940 income statement (TTM) | |
|---|---|
| Revenue | ₩3.59t |
| Cost of Revenue | ₩1.86t |
| Gross Profit | ₩1.73t |
| Other Expenses | ₩790.40b |
| Earnings | ₩936.92b |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 13.16k |
| Gross Margin | 48.16% |
| Net Profit Margin | 26.12% |
| Debt/Equity Ratio | 20.1% |
How did A207940 perform over the long term?
See historical performance and comparison